Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

21 of 23 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

B7-H4-directed ADC 2

EMBLEM-1 first patients dosed, Oct 19, 2026Registry, Feb 2027
Registry, Dec 31, 2029

CXCR1/2 inhibitor 1

Registry, Oct 2036

EGFR x MET bispecific antibody 1

No dated milestone in 2025 to 2030

gamma secretase inhibitor 1

No dated milestone in 2025 to 2030

HDAC inhibitor 1

HG146Phase 2
Registry, Dec 31, 2028

MDM2 inhibitor 1

No dated milestone in 2025 to 2030

multi-kinase TKI 1

No dated milestone in 2025 to 2030

multi-kinase TKI with chemotherapy 1

Registry, Jun 2028

MYB mRNA degrader 1

REM-422Phase 1/2
ENA 2026 late-breaking oral 5LBA (updated Phase 1), Nov 19, 2026Initial Phase 2 data (company guidance), H1 2027Registry, Sep 30, 2027

Nectin-4-directed ADC 1

Registry, Mar 2027

pan-NOTCH transcription inhibitor 1

CB-103Phase 1/2
Registry, Jun 2027

PD-1 x VEGF bispecific 1

Registry, Jul 2027

PSMA radioligand 1

No dated milestone in 2025 to 2030

TrkA inhibitor 1

VMD-928Phase 1/2
Registry, Dec 2027

TROP2-directed ADC 1

Registry, Oct 31, 2028

VEGFR multi-kinase TKI 1

Registry, Dec 2026

VEGFR TKI 1

No dated milestone in 2025 to 2030

VEGFR/MET/TAM TKI 1

Registry, Apr 2029

VEGFR2 TKI 2

RivoceranibTrials stopped
No dated milestone in 2025 to 2030
ApatinibPhase 2
No dated milestone in 2025 to 2030